Logomix

Logomix Biotechnology is a cellular system engineering company dedicated to redefining drug development as a scalable information science. Our proprietary platform, Geno-Writing™, serves as the critical interface in this transformation, enabling complex and large-scale digital genome designs to be rapidly and precisely written into the human genome. While advancing our internal program for Type 1 Diabetes, this technology functions as a a high-performance execution layer for global partners across diverse disease areas. Beyond therapeutic development, Geno-Writing™ fuels the Bio-AI stream by generating the high-fidelity iPSC libraries necessary to train foundational and virtual cell models. By closing the "design-build-test" loop, Logomix acts as the engineering engine—providing the power and precision to transition drug discovery from serendipity to an industrial, repeatable science.